Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,774.19 -1,999.35 (-3.19%) CMC Crypto 200
1,258.58 -99.43 (-7.32%)
Anavex Life Sciences Corp. (0HFR.L)
| Previous close | 3.8000 |
| Open | 3.7700 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.7680 - 3.9082 |
| 52-week range | 3.7680 - 10.4460 |
| Volume | |
| Avg. volume | 7,784 |
| Market cap | 2.174M |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5790 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript May 9, 2024 Anavex Life Sciences Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to the Anavex Life Sciences Fiscal 2024 Second Quarter Conference Call. […]
GlobeNewswireAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial
- GlobeNewswire
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will
